Search results
Results from the WOW.Com Content Network
If you’re currently pregnant, breastfeeding or planning to become pregnant, discuss mental health treatment with your healthcare provider. FDA black box warning: thoughts of death.
Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. [5] [6] It is taken by mouth.[5]The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.
Brexanolone was approved for medical use in the United States in 2019. [ 11 ] [ 15 ] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication . [ 16 ] The long administration time, as well as the cost for a one-time treatment, have raised concerns about accessibility for many women.
Federal health officials have approved the first pill specifically intended to treat severe depression after childbirth, a condition that affects thousands of new mothers in the U.S. each year.
Use during pregnancy and breastfeeding is not generally recommended. [7] It is in the serotonin modulator class of medications and is believed to work both as an SSRI and activator of the 5-HT 1A receptor. [1] Vilazodone was approved for medical use in the United States in 2011 [1] and in Canada in 2018. [8]
The US Food and Drug Administration has approved the medication zuranolone for the treatment of major depressive disorder and severe postpartum depression – making it the first FDA-approved oral ...
This is a complete list of clinically approved prescription antidepressants throughout the world, ...
The Food and Drug Administration (FDA) has approved the first pill to treat postpartum depression (PPD), the agency announced Friday. Zurzuvae is the market’s first pill medication for the ...